Evidence map›Paper›PMID 32098890›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2020

Harnessing Population Pedigree Data and Machine Learning Methods to Identify Patterns of Familial Bladder Cancer Risk.

Heidi A Hanson, Claire L Leiser, Brock O'Neil, Christopher Martin, Sumati Gupta, Ken R Smith, Christopher Dechet, William T Lowrance, Michael J Madsen, Nicola J Camp

Open access · greenAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Germline whole-exome sequencing revealsJournal for immunotherapy of cancer · 2025
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Heidi A HansonPopulation Sciences, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah. heidi.hanson@hci.utah.edu.
Claire L LeiserPopulation Sciences, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.
Brock O'NeilDivision of Urology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Christopher MartinDivision of Urology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-0534-6006
Sumati GuptaDivision of Oncology, Department of Medicine, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.
Ken R SmithPopulation Sciences, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.
Christopher DechetDivision of Urology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-0534-6006
William T LowranceDivision of Urology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Michael J MadsenPopulation Sciences, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.
Nicola J CampPopulation Sciences, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.ORCID 0000-0002-4788-1998
Huntsman Cancer Institute · USUniversity of Utah · USUniversity of Washington · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
Utah Building Interdisciplinary Resreach Careers in Women's Health Career Development ProgramK12HD085852 · NICHD · UNIVERSITY OF UTAH · PI VARNER, MICHAEL W. · 2015 to 2019
$2.3M
Subtyping Bladder Cancer: A Multi-omic, Exposure-informed, Genealogical Approach (MErGE)K07CA230150 · NCI · UNIVERSITY OF UTAH · PI HANSON, HEIDI ANNE · 2018 to 2021
$683k
NCATS NIH HHS UL1 TR002538NCI NIH HHS HHSN261201100016INCI NIH HHS HHSN261201800016CNCI NIH HHS HHSN261201800016INCI NIH HHS K07 CA230150NCI NIH HHS P30 CA042014NICHD NIH HHS K12 HD085852
6 · The paper itself

Abstract

backgroundRelatives of patients with bladder cancer have been shown to be at increased risk for kidney, lung, thyroid, and cervical cancer after correcting for smoking-related behaviors that may concentrate in some families. We demonstrate a novel approach to simultaneously assess risks for multiple cancers to identify distinct multicancer configurations (multiple different cancer types that cluster in relatives) surrounding patients with familial bladder cancer.

methodsThis study takes advantage of a unique population-level data resource, the Utah Population Database (UPDB), containing vast genealogy and statewide cancer data. Familial risk is measured using standardized incidence risk (SIR) ratios that account for sex, age, birth cohort, and person-years of the pedigree members.

resultsWe identify 1,023 families with a significantly higher bladder cancer rate than population controls (familial bladder cancer). Familial SIRs are then calculated across 25 cancer types, and a weighted Gower distance with K-medoids clustering is used to identify familial multicancer configurations (FMC). We found five FMCs, each exhibiting a different pattern of cancer aggregation. Of the 25 cancer types studied, kidney and prostate cancers were most commonly enriched in the familial bladder cancer clusters. Laryngeal, lung, stomach, acute lymphocytic leukemia, Hodgkin disease, soft-tissue carcinoma, esophageal, breast, lung, uterine, thyroid, and melanoma cancers were the other cancer types with increased incidence in familial bladder cancer families.

conclusionsThis study identified five familial bladder cancer FMCs showing unique risk patterns for cancers of other organs, suggesting phenotypic heterogeneity familial bladder cancer. IMPACT: FMC configurations could permit better definitions of cancer phenotypes (subtypes or multicancer) for gene discovery and environmental risk factor studies.

Indexed as

Machine LearningAdolescentAdultAgedAged, 80 and overDatabases, FactualData CollectionData MiningFemaleGenetic HeterogeneityGenetic Predisposition to DiseaseHumansIncidenceMaleMiddle AgedNeoplastic Syndromes, Hereditary

Identifiers

PMID32098890
PMCPMC7196496
OpenAlexW3008923826

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.